Overall rank by patents
#44,372
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Acosta holds 5 US patents across 3 technology areas, rank #44,372 of 50,000 tracked assignees.
Acosta Medical Group has been granted 5 US utility patents between 2020 and 2023, placing Acosta Medical Group at rank #44,372 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.4 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Acosta Medical Group is one of the more focused assignees in the PatentsView dataset. By volume, Acosta sits between Acesion Pharma APS (5 patents, rank #44,368) and ACP Ltd. (5 patents, rank #44,376) - the closest US assignees by grant volume. The composite Innovation Score of 43.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Acosta Medical Group's 18.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Acosta Medical Group against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ACESION PHARMA APS
5 patents
ACH Food Companies, Inc.
5 patents
ACHERNARTEK INC.
5 patents
ACM RESEARCH, INC.
5 patents
ACOUSORT AB
5 patents
ACOUSTICEYE LTD
5 patents
ACOUVA, INC.
5 patents
ACP Ltd.
5 patents
ACOSTA MEDICAL GROUP
5 patents
What this shows Acosta holds 5 patents at rank #44,372, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,372 in granted patent volume.
Other assignees with the most granted patents in Acosta's primary technology class.
Acosta's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
43 Top 28% higher than 72% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 20.0% |
| 2022 | 2 | 40.0% |
| 2023 | 2 | 40.0% |
Top 3 of 3 technology areas
Overall rank by patents
#44,372
Across all tracked assignees
43.4 out of 100
How to use this portfolio
Acosta's 5 grants land it in the top 28% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.